Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells
The interaction with platelets is of crucial importance for tumor cells passing through hematogenous metastasis. Platelets protect cancer cells from immune surveillance and exhibit many other prometastatic effects. Notably, platelets can change the epithelial tumor phenotype, a process termed epithe...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-10-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/23/10/2690 |
id |
doaj-f813b550d3214f0cb95b548f45a0fd3b |
---|---|
record_format |
Article |
spelling |
doaj-f813b550d3214f0cb95b548f45a0fd3b2020-11-24T21:07:28ZengMDPI AGMolecules1420-30492018-10-012310269010.3390/molecules23102690molecules23102690Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer CellsJan Moritz Ponert0Lukas Maria Gockel1Svenja Henze2Martin Schlesinger3Department of Pharmacy, University of Bonn, An der Immenburg 4, 53121 Bonn, GermanyDepartment of Pharmacy, University of Bonn, An der Immenburg 4, 53121 Bonn, GermanyDepartment of Pharmacy, University of Bonn, An der Immenburg 4, 53121 Bonn, GermanyDepartment of Pharmacy, University of Bonn, An der Immenburg 4, 53121 Bonn, GermanyThe interaction with platelets is of crucial importance for tumor cells passing through hematogenous metastasis. Platelets protect cancer cells from immune surveillance and exhibit many other prometastatic effects. Notably, platelets can change the epithelial tumor phenotype, a process termed epithelial-mesenchymal transition (EMT), which confers stem cell-like properties onto tumor cells associated with an increased motility and drug resistance. The aim of the study is to investigate the impact of heparin on the platelet induced EMT program in pancreatic and prostate tumor cells. Platelet activation and interaction with cancer cells were determined by static adhesion assays. Applying ELISAs, the platelet release of EMT inducing mediators was quantified. EMT marker protein expression by tumor cells was explored by western blot and qPCR. Our data show that different tumor cell entities have different platelet binding capacities and also that a weak interaction is sufficient to change tumor cell phenotype. Additionally, unfractionated heparin (UFH) as well as low molecular weight heparin (LMWH) reduced tumor cell platelet interaction. Subsequently, attenuated platelet-derived mediator release resulted in reduced EMT marker protein and transcription factor expression by the cancer cells and decreased cell migration. These data suggest that heparin reduces platelet induced EMT program and prevents the formation of cancer cells with stem cell-like properties. This additional mechanism argues for the use of heparin in oncological applications.http://www.mdpi.com/1420-3049/23/10/2690heparinplatelettumorepithelial-mesenchymal transitionEMTcancer stem cellsenoxaparin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jan Moritz Ponert Lukas Maria Gockel Svenja Henze Martin Schlesinger |
spellingShingle |
Jan Moritz Ponert Lukas Maria Gockel Svenja Henze Martin Schlesinger Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells Molecules heparin platelet tumor epithelial-mesenchymal transition EMT cancer stem cells enoxaparin |
author_facet |
Jan Moritz Ponert Lukas Maria Gockel Svenja Henze Martin Schlesinger |
author_sort |
Jan Moritz Ponert |
title |
Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells |
title_short |
Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells |
title_full |
Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells |
title_fullStr |
Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells |
title_full_unstemmed |
Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells |
title_sort |
unfractionated and low molecular weight heparin reduce platelet induced epithelial-mesenchymal transition in pancreatic and prostate cancer cells |
publisher |
MDPI AG |
series |
Molecules |
issn |
1420-3049 |
publishDate |
2018-10-01 |
description |
The interaction with platelets is of crucial importance for tumor cells passing through hematogenous metastasis. Platelets protect cancer cells from immune surveillance and exhibit many other prometastatic effects. Notably, platelets can change the epithelial tumor phenotype, a process termed epithelial-mesenchymal transition (EMT), which confers stem cell-like properties onto tumor cells associated with an increased motility and drug resistance. The aim of the study is to investigate the impact of heparin on the platelet induced EMT program in pancreatic and prostate tumor cells. Platelet activation and interaction with cancer cells were determined by static adhesion assays. Applying ELISAs, the platelet release of EMT inducing mediators was quantified. EMT marker protein expression by tumor cells was explored by western blot and qPCR. Our data show that different tumor cell entities have different platelet binding capacities and also that a weak interaction is sufficient to change tumor cell phenotype. Additionally, unfractionated heparin (UFH) as well as low molecular weight heparin (LMWH) reduced tumor cell platelet interaction. Subsequently, attenuated platelet-derived mediator release resulted in reduced EMT marker protein and transcription factor expression by the cancer cells and decreased cell migration. These data suggest that heparin reduces platelet induced EMT program and prevents the formation of cancer cells with stem cell-like properties. This additional mechanism argues for the use of heparin in oncological applications. |
topic |
heparin platelet tumor epithelial-mesenchymal transition EMT cancer stem cells enoxaparin |
url |
http://www.mdpi.com/1420-3049/23/10/2690 |
work_keys_str_mv |
AT janmoritzponert unfractionatedandlowmolecularweightheparinreduceplateletinducedepithelialmesenchymaltransitioninpancreaticandprostatecancercells AT lukasmariagockel unfractionatedandlowmolecularweightheparinreduceplateletinducedepithelialmesenchymaltransitioninpancreaticandprostatecancercells AT svenjahenze unfractionatedandlowmolecularweightheparinreduceplateletinducedepithelialmesenchymaltransitioninpancreaticandprostatecancercells AT martinschlesinger unfractionatedandlowmolecularweightheparinreduceplateletinducedepithelialmesenchymaltransitioninpancreaticandprostatecancercells |
_version_ |
1716762749382426624 |